1. Home
  2. WLAC vs LRMR Comparison

WLAC vs LRMR Comparison

Compare WLAC & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WLAC
  • LRMR
  • Stock Information
  • Founded
  • WLAC 2024
  • LRMR N/A
  • Country
  • WLAC United States
  • LRMR United States
  • Employees
  • WLAC N/A
  • LRMR N/A
  • Industry
  • WLAC
  • LRMR Biotechnology: Pharmaceutical Preparations
  • Sector
  • WLAC
  • LRMR Health Care
  • Exchange
  • WLAC Nasdaq
  • LRMR Nasdaq
  • Market Cap
  • WLAC 172.6M
  • LRMR 183.8M
  • IPO Year
  • WLAC 2024
  • LRMR N/A
  • Fundamental
  • Price
  • WLAC $10.06
  • LRMR $2.12
  • Analyst Decision
  • WLAC
  • LRMR Strong Buy
  • Analyst Count
  • WLAC 0
  • LRMR 9
  • Target Price
  • WLAC N/A
  • LRMR $19.00
  • AVG Volume (30 Days)
  • WLAC 5.3K
  • LRMR 1.4M
  • Earning Date
  • WLAC 01-01-0001
  • LRMR 04-30-2025
  • Dividend Yield
  • WLAC N/A
  • LRMR N/A
  • EPS Growth
  • WLAC N/A
  • LRMR N/A
  • EPS
  • WLAC N/A
  • LRMR N/A
  • Revenue
  • WLAC N/A
  • LRMR N/A
  • Revenue This Year
  • WLAC N/A
  • LRMR N/A
  • Revenue Next Year
  • WLAC N/A
  • LRMR N/A
  • P/E Ratio
  • WLAC $743.53
  • LRMR N/A
  • Revenue Growth
  • WLAC N/A
  • LRMR N/A
  • 52 Week Low
  • WLAC $9.80
  • LRMR $1.61
  • 52 Week High
  • WLAC $10.19
  • LRMR $11.20
  • Technical
  • Relative Strength Index (RSI)
  • WLAC N/A
  • LRMR 44.72
  • Support Level
  • WLAC N/A
  • LRMR $2.03
  • Resistance Level
  • WLAC N/A
  • LRMR $2.33
  • Average True Range (ATR)
  • WLAC 0.00
  • LRMR 0.30
  • MACD
  • WLAC 0.00
  • LRMR -0.01
  • Stochastic Oscillator
  • WLAC 0.00
  • LRMR 11.21

About WLAC Willow Lane Acquisition Corp. Class A Ordinary Shares

Willow Lane Acquisition Corp is a blank check company.

About LRMR Larimar Therapeutics Inc.

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Share on Social Networks: